Stifel Nicolaus Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $7.50

Definitive Healthcare (NASDAQ:DH) had its price target lowered by Stifel Nicolaus from $9.50 to $7.50 in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently weighed in on DH. Canaccord Genuity Group decreased their target price on shares of Definitive Healthcare from $10.00 to $8.00 and set a hold rating for the company in a research note on Wednesday, May 8th. Barclays cut their target price on Definitive Healthcare from $7.00 to $6.00 and set an equal weight rating on the stock in a research report on Wednesday. Needham & Company LLC reissued a hold rating on shares of Definitive Healthcare in a research report on Wednesday. Morgan Stanley lowered shares of Definitive Healthcare from an overweight rating to an equal weight rating and dropped their price target for the stock from $11.50 to $9.00 in a research note on Wednesday, May 8th. Finally, JPMorgan Chase & Co. downgraded shares of Definitive Healthcare from a neutral rating to an underweight rating and reduced their price objective for the company from $7.00 to $5.00 in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. According to MarketBeat, Definitive Healthcare has a consensus rating of Hold and a consensus price target of $8.45.

Definitive Healthcare Stock Performance

NASDAQ:DH opened at $3.70 on Wednesday. Definitive Healthcare has a twelve month low of $3.19 and a twelve month high of $11.60. The firm has a market capitalization of $436.34 million, a price-to-earnings ratio of -2.11, a PEG ratio of 4.58 and a beta of 1.30. The company has a current ratio of 2.30, a quick ratio of 2.30 and a debt-to-equity ratio of 0.20. The firm’s fifty day simple moving average is $5.44 and its 200 day simple moving average is $7.04.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. The company had revenue of $63.48 million for the quarter, compared to analyst estimates of $64.00 million. As a group, equities research analysts expect that Definitive Healthcare will post 0.09 earnings per share for the current fiscal year.

Institutional Trading of Definitive Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in DH. Massachusetts Financial Services Co. MA grew its position in Definitive Healthcare by 76.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,466,514 shares of the company’s stock worth $34,457,000 after purchasing an additional 1,496,652 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Definitive Healthcare by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,331,543 shares of the company’s stock worth $34,609,000 after buying an additional 254,726 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Definitive Healthcare by 209.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,209 shares of the company’s stock valued at $161,000 after acquiring an additional 10,977 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Definitive Healthcare in the first quarter worth approximately $120,000. Finally, Swiss National Bank boosted its stake in Definitive Healthcare by 2.9% during the 1st quarter. Swiss National Bank now owns 103,300 shares of the company’s stock valued at $834,000 after purchasing an additional 2,900 shares in the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.